Highlights Luspatercept enhances erythroid maturation by binding transforming growth factor-beta ligands, and may aid in reducing the transfusion burden. The present study aimed to assess the efficacy and safety of luspatercept in patients with transfusion-dependent beta-thalassemia. The patients receiving luspatercept showed a significantly greater reduction in the transfusion burden than the placebo group. More adverse events were reported in the study group as compared to the placebo group. Authors: Β M.D. Cappellini, V. Viprakasit, A.T.
Taher, P. Georgiev, K.H.M. Kuo, T. Coates, et al. This β Journal Watch β summarizes the study titled β A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent Ξ²-Thalassemia β, published in The New England Journal of Medicine, 2020. What was the need for the study? The disease management strategies in transfusion-dependentβ¦
